At Week 52 in the Phase 2 COACH trial, once-weekly TransCon CNP plus once-weekly TransCon hGH delivered a mean change in achondroplasia-specific arm span Z-score of +1.02 in treatment-naïve children and +0.66 in previously TransCon CNP–treated children, translating to absolute arm span gains of +9.4 cm and +7.9 cm, respectively. Lumbar interpedicular distance increased by a mean of +1.7 mm and +1.1 mm in the two combination cohorts, compared with +0.6 mm reported with TransCon CNP monotherapy in the ApproaCH study. Tibial femoral angle improved with a mean Z-score change of -0.86 and a mean absolute change of -3.0 degrees on combination therapy in treatment-naïve children, versus -0.47 and -1.3 degrees at Week 52 on monotherapy. All children completed one year of treatment. Previously disclosed COACH data showed annualized growth velocity above the 97th percentile for average-stature children, without bone age acceleration or new safety concerns at one year.
The core update is the emergence of structural and proportionality signals beyond linear growth from Ascendis Pharma’s open-label Phase 2 program combining TransCon CNP (recently approved in the U.S. as YUVIWEL for achondroplasia) with TransCon hGH (approved for growth hormone deficiency, investigational in achondroplasia). COACH enrolled 21 children aged 2 to 11 years, split between TransCon CNP–naïve participants and those previously treated for a mean of 2.56 years. The company is spotlighting arm span, spinal canal dimensions, and lower limb alignment as clinically meaningful measures that align with community priorities and may forecast downstream reductions in morbidity and interventions.
Strategically, this is a label-broadening and value-building play. With monotherapy approved in the U.S. and under EMA review, the sponsor is moving quickly to frame achondroplasia outcomes around function, proportionality, and skeletal health, not just height velocity. The combination approach pairs continuous CNP exposure with sustained-release somatropin to test whether proportional growth and skeletal remodeling can be amplified without compromising safety or accelerating maturation. The tension is methodological: the new signals are derived from a small, open-label dataset and rely on cross-trial comparisons to a separate monotherapy study. Endpoints such as interpedicular distance are biologically intuitive but not yet validated as registrational outcomes, and radiographic improvements will need to link to fewer clinical events to persuade regulators and payers.
Operationally, sites and CROs should anticipate more complex, standardized imaging and anthropometry workflows if this strategy advances. Consistent lumbar measurements, lower limb alignment assessments, and precise arm span tracking will require harmonized protocols, central reads, and radiation stewardship in young children. Weekly dual injections add regimen complexity in a pediatric population and will necessitate adherence support. Regulators will scrutinize the rationale for adding growth hormone in growth hormone–sufficient children, with attention to bone age, foramen magnum and spinal parameters, cardiometabolic markers, and sleep-disordered breathing. Payers will look for evidence that combination therapy reduces surgeries, hospitalizations, or pain and disability, and will benchmark any dual-biologic cost against both medical management and orthopedic interventions.
Next, the program will need a randomized, controlled study powered to demonstrate that skeletal and proportionality gains are durable and translate into fewer procedures and complications, alongside sustained safety. Expect pressure to incorporate functional endpoints, quality-of-life measures, and time-to-intervention analyses, with longer follow-up to confirm that bone age remains appropriate. The EMA decision on TransCon CNP monotherapy will shape European trial and access strategies, and any move toward a combination label will hinge on converging evidence from imaging, clinical events, and real-world data as YUVIWEL use expands. Key watch items over the next 12–24 months include 104-week durability from COACH, protocol details for a registrational combination study, safety updates under accelerated growth conditions, and early payer reactions to proportionality and spine metrics as proxies for long-term benefit.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
